Cell therapy weekly: successful preclinical studies lay the foundation to advance organ regeneration technology

Written by RegMedNet

This week: LyGenesis (PA, USA) announces the publication of four studies demonstrating success of their organ regeneration technology, FDA grants Rare Pediatric Disease designation for Editas Medicine’s (MA, USA) experimental autologous cell medicine and Autolus Therapeutics and CGT Catapult (both London, UK) collaborate to enable commercial manufacture of CAR-T therapies. The news highlights: Successful preclinical studies lay the foundation for the advancement of organ regeneration technology FDA grants rare pediatric disease designation to cell therapy to treat sickle cell disease Collaboration established to enable commercial manufacture of CAR-T therapies Successful preclinical studies lay the foundation for the advancement of organ...

To view this content, please register now for access

It's completely free